Project Grant R21AG091815
Award Date
4/1/25
Completion Date
3/31/27
Dollars Obligated
$453K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Cooperative Agreement awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) provides $810,698 in funding to Trustees of Boston University, doing business as Boston University Medical Campus, to conduct research on the impact of APOE genotype on Alzheimer's disease (AD) risk and underlying biological mechanisms.
The project aims to: 1) Identify new APOE genotype-mediated AD associations using large genetic datasets, 2) Perform...
This $831,583 Project Grant award from the National Institute on Aging's (CFDA 93.866) Aging Research program will support a study on the physiological mechanisms underlying microvascular impairment in adults with elevated genetic risk for Alzheimer's disease. The five-year project, led by The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to elucidate how the APOE-E4 genetic risk factor contributes to reductions in cerebral blood flow and oxygen...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $805,738 to the Battelle Memorial Institute's Pacific Northwest National Laboratory to conduct research on the impact of brain lipoprotein structure and composition on amyloid beta metabolism and Alzheimer's disease. The key objectives are to: 1) Assess how APOE isoforms affect brain lipoprotein distribution, composition, and ability to bind amyloid beta, and 2) Determine the...
This federal Project Grant award for $2,431,261, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), supports a research project to investigate the role of reelin signaling and receptor splicing in Alzheimer's disease (AD). The key goals are to:
Determine if alternative splicing of the reelin receptors APOER2 and VLDLR impacts AD risk.
Assess the functional consequences of receptor splice variants on reelin binding and signaling, and how this may...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,521,606.00 to Trustees of Boston University, doing business as Boston University Medical Campus, to investigate the role of the microRNA miR-129-2 in regulating vulnerability and tau accumulation in the entorhinal cortex layer II neurons during Alzheimer's disease.
The key objectives are to: 1) Map the expression patterns of miR-129-2 in the entorhinal cortex of mouse models and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) to The Roskamp Institute, Inc. in Sarasota, Florida provides $449,460 in funding to support research investigating the role of cerebrovascular dysfunction and bioenergetic deficits in the increased Alzheimer's disease risk associated with the APOE4 genetic variant. The research aims to determine how APOE4 disrupts L-carnitine-mediated bioenergetic pathways in brain endothelial and mural cells, and...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $1,170,000.00 in funding to Brown University to conduct a comprehensive study of the APOE gene and the noncoding RNA AANCR to advance Alzheimer's disease treatment.
The primary objectives are to:
Elucidate how the AANCR enhancer RNA regulates APOE transcription and how AANCR itself is modulated to maintain cell-type specific and stress-induced APOE...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse...
The Project Grant award R01AG079283, funded by the National Institute on Aging (CFDA 93.866 Aging Research program), will support research on the characterization of amyloid protein aggregation and its interactions with apolipoprotein E (APOE) in the context of Alzheimer's disease. The $748,641 award, with a project period from May 2024 to April 2029, will utilize advanced mass spectrometry-based protein footprinting techniques, including hydrogen/deuterium exchange and fast photochemical...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $433,824 to the J. David Gladstone Institutes in San Francisco, CA to investigate how the Alzheimer's disease risk factor APOE4 disrupts the maturation and integration of adult-born dentate granule cells in the hippocampus. The research aims to elucidate the underlying transcriptomic changes and electrophysiological alterations that lead to hyperexcitability in these neurons, with the...